Shattuck Labs Inc. (STTK): Price and Financial Metrics
GET POWR RATINGS... FREE!
STTK POWR Grades
- STTK scores best on the Sentiment dimension, with a Sentiment rank ahead of 87.82% of US stocks.
- STTK's strongest trending metric is Quality; it's been moving down over the last 178 days.
- STTK's current lowest rank is in the Momentum metric (where it is better than 3.89% of US stocks).
STTK Stock Summary
- STTK's went public 1.95 years ago, making it older than only 8.17% of listed US stocks we're tracking.
- Of note is the ratio of SHATTUCK LABS INC's sales and general administrative expense to its total operating expenses; just 7.97% of US stocks have a lower such ratio.
- Revenue growth over the past 12 months for SHATTUCK LABS INC comes in at 1,663.66%, a number that bests 99.33% of the US stocks we're tracking.
- Stocks with similar financial metrics, market capitalization, and price volatility to SHATTUCK LABS INC are KZIA, ABUS, SYBX, ATHX, and FHTX.
- Visit STTK's SEC page to see the company's official filings. To visit the company's web site, go to www.shattucklabs.com.
STTK Valuation Summary
- STTK's price/sales ratio is 4.2; this is 90.91% higher than that of the median Healthcare stock.
- Over the past 23 months, STTK's EV/EBIT ratio has gone up 23.6.
Below are key valuation metrics over time for STTK.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| STTK | 2022-09-09 | 4.2 | 0.6 | -2.2 | -1.7 |
| STTK | 2022-09-08 | 4.6 | 0.7 | -2.4 | -1.9 |
| STTK | 2022-09-07 | 4.4 | 0.6 | -2.3 | -1.8 |
| STTK | 2022-09-06 | 4.3 | 0.6 | -2.3 | -1.7 |
| STTK | 2022-09-02 | 4.3 | 0.6 | -2.2 | -1.7 |
| STTK | 2022-09-01 | 4.3 | 0.6 | -2.2 | -1.7 |
STTK's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- STTK has a Quality Grade of C, ranking ahead of 29.15% of graded US stocks.
- STTK's asset turnover comes in at 0.006 -- ranking 405th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows STTK's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.006 | 1 | -0.376 |
| 2020-12-31 | 0.050 | 1 | -0.381 |
STTK Price Target
For more insight on analysts targets of STTK, see our STTK price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $48.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
STTK Stock Price Chart Interactive Chart >
STTK Price/Volume Stats
| Current price | $2.70 | 52-week high | $21.42 |
| Prev. close | $2.66 | 52-week low | $2.59 |
| Day low | $2.60 | Volume | 36,700 |
| Day high | $2.86 | Avg. volume | 176,807 |
| 50-day MA | $3.60 | Dividend yield | N/A |
| 200-day MA | $4.75 | Market Cap | 114.43M |
Shattuck Labs Inc. (STTK) Company Bio
Shattuck is a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC) platform, a novel class of dual-function fusion proteins with applications in oncology and autoimmune disease. The company’s lead program, SL-279252 (PD1-Fc-OX40L), is being studied in a Phase I trial in collaboration with Takeda Pharmaceuticals. Its technology focuses on immuno-oncology research targeted towards patients with many cancer types, including melanoma, lung, and bladder, by endowing one molecule with multiple functions, with applicability across the entire spectrum of human disease that enables medical researchers to find a quick and painless detection of malignancy for later-stage cancer patients.
Latest STTK News From Around the Web
Below are the latest news stories about SHATTUCK LABS INC that investors may wish to consider to help them evaluate STTK as an investment opportunity.
Shattuck Labs Announces Participation in Upcoming September ConferencesAUSTIN, TX & DURHAM, NC, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in two investor conferences in September 2022. Presentation Details Conference: Citi’s 17th Annual BioPharma ConferenceFormat: Targeted |
We Think Shattuck Labs (NASDAQ:STTK) Needs To Drive Business Growth CarefullyThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com... |
Shattuck Labs (STTK) Receives a Buy from NeedhamNeedham analyst Gil Blum reiterated a Buy rating on Shattuck Labs (STTK - Research Report) today and set a price target of $21.00. The company's shares closed today at $3.71.According to TipRanks, Blum is an analyst with an average return of -2.4% and a 44.38% success rate. Blum covers the Healthcare sector, focusing on stocks such as CTI BioPharma, Sarepta Therapeutics, and Crispr Therapeutics AG.The word on The Street in general, suggests a Strong Buy analyst consensus rating for Shattuck Labs with a $20.50 average price target, which is a 452.56% upside from current levels. In a report released today, H.C. |
Analysts’ Top Healthcare Picks: Taysha Gene Therapies (TSHA), Shattuck Labs (STTK)There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Taysha Gene Therapies (TSHA – Research Report) and Shattuck Labs (STTK – Research Report) with bullish sentiments. Taysha Gene Therapies (TSHA) Needham analyst Gil Blum reiterated a Buy rating on Taysha Gene Therapies today and set a price target of $20.00. The company's shares closed last Thursday at $4.17, close to its 52-week low of $2.33. According to TipRanks. |
Shattuck Labs Reports Second Quarter 2022 Financial Results and Recent Business Highlights– Enrollment of Phase 1B clinical trial of SL-172154 in combination with liposomal doxorubicin in platinum-resistant ovarian cancer expected to begin in Q3’2022 with initial combination data expected in 1H’2023 – – Dose escalation ongoing for Phase 1 clinical trial of SL-172154 in acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) with initial monotherapy and combination dose-escalation data expected in 1H’2023 – – Presented preclinical proof-of-concept data demonstr |
STTK Price Returns
| 1-mo | -15.09% |
| 3-mo | -35.10% |
| 6-mo | -40.27% |
| 1-year | -84.63% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -68.27% |
| 2021 | -83.76% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...